Is Medicamen Biotech Ltd halal to invest in?

According to Musaffa's Shariah screening methodology, Medicamen Biotech Ltd (MEDICAMEQ.NS) is currently classified as HALAL as of January 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Medicamen Biotech Ltd a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Medicamen Biotech Ltd using these criteria to determine its compliance status.

Can Muslims buy shares of Medicamen Biotech Ltd?

Muslim investors may consider investing in Medicamen Biotech Ltd if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Medicamen Biotech Ltd classified as HALAL?

Musaffa determines the Shariah status of Medicamen Biotech Ltd by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Medicamen Biotech Ltd updated?

The Shariah compliance status of Medicamen Biotech Ltd may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Medicamen Biotech Ltd become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Medicamen Biotech Ltd?

You can check the latest Shariah compliance status of Medicamen Biotech Ltd on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

MEDICAMEQ.NS Shariah Compliance

Screening Methodology: AAOIFI

HALAL

Last Updated: January 01, 2026

Report Source: 2026 2nd Quarter Report

Medicamen Biotech Ltd. Stock Analysis MEDICAMEQ.NS

India Health Care Nano Cap Report: Q2, 2026

Medicamen Biotech Ltd. engages in the manufacture and marketing of pharmaceutical formulations. The firm is principally engaged in generic finished dosage forms (FDF), Oncology formulations and research and development services to cater to the needs of the global pharmaceutical industry. The Company’s focus areas include antibiotics, hypertension, general pain management, cardiovascular, diabetics and oncology formulations. In cardiology, the Company is delivering effective treatments for heart-related conditions. Its CNS products address neurological disorders, while its diabetology solutions focus on advanced diabetes management. The company also contributes to the global fight against malaria with its anti-malarial medications. Additionally, the Company offers essential vitamins, antibiotics for bacterial infections, and comprehensive pain management solutions. Its oncology products include Abiraterone acetate, Anastrozole, Bicalutamide, Bendmustine HCL, and others.

Key Statistics of Medicamen Biotech Ltd (MEDICAMEQ.NS)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

₹268.00₹278.00

Today's Open

₹275.00

Volume

14.10K

P/E Ratio (TTM)

52.14

52 Week Range

₹216.95₹455.95

Market Cap

3.51B

Avg. Volume

26.86K

Dividend Yield

0.34%

Financial Metrics & Statements of Medicamen Biotech Ltd (MEDICAMEQ.NS)

FAQ's for Medicamen Biotech Ltd (MEDICAMEQ.NS)

According to Musaffa’s Shariah screening methodology, Medicamen Biotech Ltd (MEDICAMEQ.NS) is currently classified as HALAL as of January 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.